We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Aduhlem is contributing to a 14.5 percent increase in 2022 Medicare Part B premiums, even though the Centers for Medicare and Medicaid Services (CMS) hasn’t yet decided whether it will pay for the controversial Alzheimer’s treatment. Read More
The UK’s National Institute for Health and Care Excellence (NICE) has recommended that the National Health Service (NHS) not offer BioMarin Pharmaceutical’s Vimizim (elosulfase alfa) for treating mucopolysaccharidosis type 4A syndrome, also known as Morquio A syndrome. Read More
Three days before the clock was set to run out on the legality of Janet Woodcock serving as acting commissioner of the FDA, President Biden has announced that he will nominate Robert Califf to take a second turn at occupying the top spot at the agency. Read More
In order to be cost-effective relative to standard Alzheimer’s care, Aduhelm — the newly approved Alzheimer’s antibody — would have to cost no more than $3,000 per year, rather than the current $56,000 price tag. Read More
The European Medicines Agency (EMA) has recommended including transverse myelitis, a rare form of spinal inflammation, to the list of Johnson & Johnson (J&J) COVID-19 vaccine side effects. Read More
Moderna and the National Institutes of Health (NIH) are in a patent dispute over the company’s messenger RNA (mRNA)-based COVID-19 vaccine developed with the aid of government scientists. Read More
Ten of the nation’s highest-ranked hospitals charge health insurance companies and patients paying out of pocket far more than the amount Medicare pays for several infused drugs, according to a report published in the Nov. 8 issue of the Journal of the American Medical Association (JAMA) Internal Medicine. Read More